Prosecution Insights
Last updated: April 19, 2026
Application No. 18/664,616

SILK FIBROIN-CONTAINING COMPOSITION AND METHODS OF USE THEREOF

Non-Final OA §102
Filed
May 15, 2024
Examiner
REYNOLDS, FRED H
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Georgetown University
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
2y 10m
To Grant
72%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allow Rate
269 granted / 815 resolved
-27.0% vs TC avg
Strong +40% interview lift
Without
With
+39.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
104 currently pending
Career history
919
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
13.2%
-26.8% vs TC avg
§112
26.5%
-13.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 815 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicant’s election of group I and silk fibroin with perfluorooctylbromide in the replies filed on 24 Nov, 2025 and 13 Jan, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Applicants have elected a formulation comprising silk fibroin with perfluorooctylbromide. A search was conducted for this invention, and a reference rendering it obvious was found. As a result, claim 1 was examined and claims 2, 3, 7, 9, 10, 13, 15, 17, 22-25, 28, 33, 36, 41, 44, 46, and 49 were withdrawn from consideration. Applicants state that they believe the election reads on claims 2, 3, and 49, but claims 2 and 3 require components not elected, as does claim 49, based on its dependency from claim 13. Thus, these claims are properly withdrawn. Claims Status Claims 1-3, 7, 9, 10, 13, 15, 17, 22-25, 28, 33, 36, 41, 44, 46, and 49 are pending. Claims 2, 3, 7, 9, 10, 13, 15, 17, 22-25, 28, 33, 36, 41, 44, 46, and 49 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention or species, there being no allowable generic or linking claim. Election was made without traverse in the replies filed on 24 Nov, 2025 and 13 Jan, 2026. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gazit et al (US 20090214649, cited by applicants). Gazit et al discuss scaffolds comprising an oxygen carrier and a matrix (abstract). The matrix can be silk (paragraph 76), which is a silk fibroin (paragraph 77). The oxygen carrier can be a perfluorocarbon, such as perfluorooctylbromide (paragraph 88). This is a composition comprising silk fibroin and perfluorooctylbromide, anticipating claim 1. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FRED REYNOLDS whose telephone number is (571)270-7214. The examiner can normally be reached M-Th 9-3:30. Examiner interviews are available via telephone and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /FRED H REYNOLDS/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

May 15, 2024
Application Filed
Oct 31, 2025
Response after Non-Final Action
Nov 24, 2025
Response after Non-Final Action
Feb 23, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590131
ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES
2y 5m to grant Granted Mar 31, 2026
Patent 12576132
ISTHMIN 1 FOR TREATMENT OF LUNG INFLAMMATION
2y 5m to grant Granted Mar 17, 2026
Patent 12559532
EMBRYONIC ANGIOGENESIS MARKERS AND DIAGNOSTIC AND THERAPEUTIC STRATEGIES BASED THEREON
2y 5m to grant Granted Feb 24, 2026
Patent 12551535
PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
2y 5m to grant Granted Feb 17, 2026
Patent 12545707
PEPTIDIC MACROMOLECULAR ASSEMBLIES
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
72%
With Interview (+39.5%)
2y 10m
Median Time to Grant
Low
PTA Risk
Based on 815 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month